Abstract: Objective To evaluate the toxicity and side-effects of Epirubicin to heart from micro-pump and from intravenous drip medication using the method of the quantitative tissue velocity(QTVI)ofthe myocardium. Methods Sixty-five cases are chosen for the study, with 46 cases diagnosed as breast cancer and 19 of malignant lymphoma. The cases were divided into two groups: Micro-pump (MP) group (n=31) and Intravenous Drip (ID)group (n=34), and all of them are given the same dosage ofEpirubicin （70mg/m2）. Quantitative analyses of QTVI parameters are made before and after each chemotherapy of the myocardial segmentation in each cardiac cycle. In addition, measurements were also made of the left ventricular internal diameter at end-diastole (LVIDd), the interventricular septal thickness at end- diastole (IVSTd), the left ventricular posterior wall thickness at end- diastole (LVPWTd), and left ventricular internal diameter at end-systole (LVIDs); and the left ventricular ejection fraction (LVEF) was also calculated. Meanwhile, pulsed Doppler ultrasound was employed to measure the cardiac venous flow of the mitral valve area in the apical four chamber view,the peak velocity of blood flow when the left ventricular was at its early diastole (E) and that of the left ventricular at its early systole (A), namely the ratio of E/A. Results Compared with T0(P＞0.05), no differences are observedin the LVIDd, IVSTd, LVPWTd, E/A ratio and LVEF between the MP and ID group at theend of each chemotherapy. But after four courses of chemotherapy with an Epirubicin dosage of280/m2, the velocity of early diastolic (Ve) begins to slow down in the MP group while the velocity of atrial contraction (Va) increases. As a result, the Ve/Va ratio falls in the MPG group. In contrast, at the end of the thirdchemotherapy with an Epirubicin dosage of210/m2, the QTVI yields the same results in the ID group. Conclusion Theapplication ofQTVI in monitoring the toxicityandside-effects of Epirubicin tothe heart iseffective.Compared with the observationsinthe ID group, Epirubicin administrated in the MP group tends to lessen the toxicity andside-effectstothe heart in chemotherapy.